Changes in clinical practice should be driven by relevant and reliable evidence. Hence, adoption of a new therapy requires demonstrating that it provides (causes) benefit. Such evidence is generally obtained from intent-to-treat analyses of randomized clinical trials (RCTs). In this paper, we review other approaches to assessing the causal relationship between treatments and outcomes: (1) inference from non-randomized (observational) studies, (2) analysis of randomized studies where patients received treatments other than those to which they were randomized and (3) analysis of studies where the outcome of interest is sometimes unobservable because of a competing event (competing risks). We conclude that for the practice-changing demonstration of a favorable benefitto-risk ratio, the gold standard is the intent-to-treat analysis of RCTs. At the same time, we illustrate how careful application of special statistical methods for assessment of treatment-outcome causation can be instrumental in complementing existing randomized evidence and guiding design of future research.
Introduction
Sustained advancement of medical care requires that adoption of a new therapy to wide clinical practice be based on reliable evidence of its benefit-to-risk ratio. The reason why the randomized clinical trial (RCT) is widely recognized as the gold standard for evaluation of therapeutic interventions is that random treatment assignment allows one to establish causation (the intervention causes improvement in outcome) and to obtain unbiased assessment of the treatment effect without reliance on unverifiable assumptions. That is, one can conclude that the observed difference in outcome between patients randomly assigned to the experimental and control treatments is caused by administration of the experimental treatment (with a degree of confidence inversely proportional to the sample size). Sometimes, in an aggressive disease with a homogeneous natural course, evidence from nonrandomized studies could be sufficient to convincingly demonstrate a causal relationship between a treatment and clinical benefit, for example, imatinib was widely accepted (and approved by US Food and Drug Administration) as an effective therapy for accelerated and blast phases of CML based on several single-arm phase II studies that demonstrated a high rate of durable hematologic responses. 1 Because of complexity, cost and time considerations, there is considerable interest in developing statistical methodologies that would more generally provide evidence of causal effect without having to compare randomized interventions. In this review, we will discuss methods that intend to assess the causal relationship between a treatment and outcome using (1) non-randomized (observational) data, (2) data from randomized trials where patients received treatments other than those to which they were randomized and (3) data from studies with competing risks where the outcome of interest is sometimes unobservable because of a competing event. 2, 3 Non-randomized studies
The initial inference about the efficacy of a new treatment is typically made using data from non-randomized studies that compare outcomes of patients who received the new treatment vs outcomes of patients who received (control) standard therapy (usually in different studies). The key feature of this type of comparison is that the determination of which patient received which therapy is based on patent characteristics (and treatment preferences) and treating physician clinical judgment (at the time and in the institution in which the patient was treated).
Some studies treat all patients with a new therapy and then compare their outcomes to patient outcomes observed in previous studies of presumably similar patients ('historical controls'). However, patient heterogeneity, selection bias and time trends in standard of care make such comparisons very unreliable. 4, 5 This is especially problematic in highly selected subpopulations in diseases with heterogeneous natural history. A cautionary example of misguided reliance on non-randomized data is provided by the history of HDCT (high-dose chemotherapy) with BMT in breast cancer. In the 1980s and the first half of the 1990s, prominent and persistent reporting of large potential benefits by non-randomized pilot studies resulted in 'premature enthusiasm' about the treatment. 6 The premature enthusiasm (and the fact that the treatment involved high doses of approved chemotherapy) resulted in HDCT being increasingly used in routine practice. 7 This, in turn, complicated patient recruitment and conduct of definitive randomized trials and exposed many patients to unnecessary toxicity 8 (it is estimated that over 40 000 breast cancer-related transplants were performed in 1990s 9 ). This happened while the potential for selection and publication bias in the non-randomized pilot (phase II) studies had been widely acknowledged and well documented. [10] [11] [12] [13] [14] Careful evaluation of ABMT registry data confirmed the sensitivity of the outcome to the patient prognostic characteristics and the potential for selection bias. 15 It took results from several well-designed RCTs showing no benefit and increased toxicity to convince the clinical community of the inefficacy of HDCT.
Some of the biases inherent in comparison of outcomes between different studies can be reduced by employing prospective cohort studies that follow patients receiving the new and control treatments using predefined eligibility criteria and standardized data collection. However, even with this approach, potential for selection bias remains a major problem. For example, a prospective cohort study 16 compared proteolytic enzyme therapy vs gemcitabine-based chemotherapy in advanced pancreatic cancer: after central review of carefully defined entry criteria, eligible patients were allowed to select the therapy they preferred and then were uniformly followed up for survival. The study reported an OS benefit for the chemotherapy arm: a hazard ratio of 6.96 (P-value o0.001), with median survival of 14.0 and 4.3 months on chemotherapy and enzyme arms, respectively. As stated in the accompanying editorial, this dramatic effect cannot be trusted 17 as it is clearly a result of selection bias (even though the authors found no statistically significant difference between the arms in major known baseline prognostic factors such as Eastern Cooperative Oncology Group (ECOG) performance status and disease stage). Sophisticated statistical techniques can be used in an attempt to further adjust for the residual bias in prospective cohort studies. Consider a report by Grothey et al. 18 that used the BRiTE cohort study to evaluate benefit of continuing bevacizumab beyond progression (BBP) in metastatic colorectal cancer patients receiving bevacizumab as a part of their first-line therapy. The report used various modeling methods and sensitivity analyses to adjust for known confounders. In addition to the known baseline prognostic factors, the authors tried to minimize potential differences between the BBP and NO-BBP patients by including factors like timeto-first-progression and best first-line response in modeling the expected BBP benefit. The resulting model estimated that continuing bevacizumab past progression produced a dramatic 10-month improvement in OS (relative to discontinuing bevacizumab at progression): 19.2 months vs 9.5 months median OS, with a hazard ratio of 0.49 (95% confidence interval: (0.41, 0.58)). However, this nonrandomized estimate of OS effect requires cautious interpretation in the context of the related definitive (randomized) evidence: the estimated effect more than doubles OS improvements reported in randomized phase III studies of bevacizumab in metastatic colorectal cancer (both first and second line). 19 In particular, the estimated benefit of BBP is inconsistent with the most relevant randomized benchmark provided by E3200 that reported that the addition of bevacizumab to second-line FOLFOX4 therapy improved OS by 2 months: 12.9 vs 10.8 median OS with hazard ratio of 0.75 (95% confidence interval: (0.63, 0.89)). 19, 20 Note that since E3200 was conducted in a bevacizumab-naive population, its treatment effect would be expected to be larger than that in patients progressing after the first-line bevacizumab-containing therapy (the population considered in Grothey et al.
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). In summary, the validity of a causal-effect claim from a non-randomized study requires the absence of any unaccounted-for systematic differences in patient characteristics, clinical care and data-collection techniques between the groups being compared. Since this requirement can never be reliably ascertained and has empirically been shown to be false in a number of major public-health settings (Table 1) , non-randomized studies generally do not provide sufficiently reliable evidence for changing clinical practice. Table 1 Examples of important medical and surgical interventions supported by non-randomized studies that were later shown to be ineffective or harmful in randomized trials
Treatment and clinical setting References
High-dose chemotherapy with bone marrow transplantation for breast cancer 6, 14 Hormone replacement therapy for coronary heart disease in menopausal women 50, 51 b Carotene for lung cancer in smokers [52] [53] [54] Vitamin E for coronary heart disease in high-risk patients [55] [56] [57] [58] Arthroscopic knee surgery for osteoarthritis 59, 60 Vitamin C for coronary heart disease 61, 62 Blood transfusion to maintain hemoglobin X10 mg/dL in critically ill patients 63, 64 High-dose dialysis in patients undergoing maintenance hemodialysis 65, 66 Extracranial-intracranial bypass for carotid artery stenosis 67, 68 Intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma 69, 70 Diethylstilbestrol for prevention of spontaneous abortions 71 Assessing treatment-outcome causation B Freidlin and EL Korn
Non-randomized (non-intent-to-treat) comparisons in randomized studies
In a typical RCT, patients are randomly assigned to either receive a new (experimental) therapy or a control (standard) therapy. An intent-to-treat analysis that compares outcomes of patients randomized to the experimental arm vs the control arm regardless of treatment they actually received provides a framework for a valid assessment of causal relationship between the new treatment and clinical outcome free from additional assumptions. For practical reasons, it may be desirable to analyze RCT data in a manner different than intent-to-treat in order to adjust for treatments the patients actually received. A number of statistical methods (collectively referred to as 'causal inference' in the statistical literature) have been proposed for this purpose. However, these causal-inference methods necessarily require making some unverifiable assumptions.
Adjusting for subsequent therapies received at progression For an RCT evaluating an experimental cancer treatment, prolongation of OS is generally the most relevant measure of clinical benefit. However, the availability of active therapies that are given subsequently to the randomized treatment when a patient's condition worsens (for example, salvage therapies given at progression or relapse) may complicate interpretation of OS results. There are two distinct cases: in the first case, the same subsequent therapy is used in both arms. In the second case, the control-arm patients crossover to the experimental therapy (this design is essentially testing the benefit of giving the experimental treatment earlier vs later). In either case, if the therapies that are given subsequently to the randomized treatment in both treatment arms follow the current standard of care (as practically always is the situation in the first case) then the observed (intent-to-treat) OS difference represents the relevant clinical benefit. 21 (Note that this includes first-line RCTs of effective second-line therapies because the controlarm patients receive the experimental therapy as secondline therapy as part of the standard of care).
In contrast to the situation where the subsequent therapies are part of the standard of care, when a new therapy is evaluated in a particular disease for the first time, crossover of the control-arm patients to the experimental therapy (at the time of progression or when the definitive PFS results are released) confounds evaluation of clinical benefit. This is illustrated by the growing number of highprofile RCTs that demonstrate biologic activity of novel anticancer agents (as measured by improvement in PFS), without providing an interpretable estimate of the agent's clinical benefit. [22] [23] [24] [25] [26] In these trials, observing no or little OS difference between the arms could be explained by either of the two scenarios: (1) the experimental treatment provides important improvement in OS that is, not observed because both arms receive the experimental treatment or (2) the experimental treatment provides no improvement in OS (the observed PFS benefit would not translate into benefit even if there were no crossover).
If no OS improvement is observed in a trial where a nontrivial proportion of the control-arm patients crossed over to the experimental therapy, one can attempt to distinguish between the two scenarios by estimating hypothetical OS improvement that would had been observed if no patients had crossed over. For RCT designs that offer crossover to control-arm patients only after the definitive (positive) PFS trial result is reached 27 (as opposed to the designs that automatically cross patients at progression 23 ), a simple analysis approach that censors all control-arm patients at the time the crossover is offered allows one to draw a valid assessment of treatment-effect causation without making unverifiable assumptions. This approach assumes no prognostic time trends in the study population, an assumption that can be verified by comparing outcomes of early-vs later-accrued patients in the experimental arm. Because the timing of censoring is independent of individual patient outcome, this analysis provides an unbiased estimate of the OS treatment effect in the absence of crossover (albeit at a cost of some loss of statistical power). For example, when a renal cancer trial of sorafenib vs placebo reported positive PFS results, 27 all placebo-arm patients on that trial were offered sorafenib (the original trial design did not allow crossover at progression). The intent-to-treat comparison of sorafenib vs placebo arms did not find a significant OS improvement (hazard ratio ¼ 0.88; P ¼ 0.146). 28 However, an additional analysis that uniformly censored placebo-arm patients at the time of allowed crossover suggested that sorafenib offers significant OS benefit in this setting (hazard ratio ¼ 0.78; P ¼ 0.029). 28 Unfortunately, the above censoring-at-crossover method does not work for RCT designs with automatic crossover at progression. In these designs, the timing of censoring for each patient is likely to be related to his/her outcome, so that the OS prognosis for patients who crossed over is likely to be different from that for patients who did not crossover (thus inducing informative censoring 29 ). In this case causalinference methods have to be used (after making additional assumptions). One method 30 used [31] [32] [33] is based on a number of unverifiable assumptions including (1) the treatment has the same effect on OS regardless of when it is given in the course of the patient's disease (for example, 2 months of treatment given upfront or at progression result in the same 1-month improvement in OS) and (2) the absolute benefit of treatment is less than the duration of treatment (for example, OS improvement from 2 months of treatment is always o2 months). A key property of this method is that for a trial with an observed small intent-to-treat OS effect, it would generally suggest a larger OS effect. On the other hand, the method cannot conclude a statistically significant OS effect when the observed intent-to-treat effect is not statistically significant.
A different causal-inference approach to adjusting for crossover is the inverse probability of censoring weighting method. 34 The method attempts to minimize the bias due to difference between crossover and no-crossover populations by weighting up the data from the observed non-crossover patients by an amount inversely proportional to the probability of crossing over. This is done by identifying prognostic patient subgroups with similar probability of crossover using a statistical model. It should be kept in mind, however, that validity of inverse probability of censoring weighting method depends on the assumption that this model captures all confounding factors that are associated with both the probability of crossover and OS prognosis for a given patient. Consider the BIG 1-98 study 35 that included a randomized comparison of 5 years of tamoxifen vs 5 years of letrozole in hormone-receptorpositive early breast cancer; after the initial trial results demonstrated disease-free survival advantage, 25.2% of tamoxifen-arm patients selectively crossed over to letrozole. In the intent-to-treat analysis, OS improvement (on the letrozole arm) did not reach statistical significance: hazard ratio ¼ 0.87 with 95% confidence interval: (0.075, 1.02). To adjust for the effect of crossover, Colleoni et al. 36 applied the inverse probability of censoring weighting method that estimated a statistically significant OS improvement in the absence of crossover: hazard ratio ¼ 0.82 with 95% confidence interval: (0.70, 0.95). The reliability of this result, however, depends on the unverifiable modeling assumptions and needs to be 'viewed in light of any potential bias.' 37 Adjusting for subsequent therapies received at achieving minimal tumor-burden reduction A somewhat different RCT setting where intervening therapies complicate OS comparisons is when additional therapy is given to the patients achieving some minimal reduction in tumor burden (for example, transplant or maintenance given to patients achieving CR on the randomly assigned study treatment). If the proportion of patients receiving the subsequent therapy differs between the arms (for example, different transplant rates in a study comparing two induction regimens), then the interpretation of the OS comparisons can be complicated. Similarly to the above case, if the subsequent therapies follow the current standard of care, then the observed OS intent-to-treat differences represent the relevant clinical benefit of the experimental therapy. However, exploratory analyses estimating relative outcomes of different sequences of treatments may be useful in generating hypothesis for optimizing treatment strategy. Consider a randomized trial of topotecan þ cyclophosphamaide vs topotecan alone in recurrent neuroblastoma. 38 Intent-to-treat analysis indicated no difference in OS. However, some of the patients on study received auto-SCT, with patients responding to the initial chemotherapy regimen more likely having subsequent auto-SCT. It is theoretically possible that a suboptimal pattern of auto-SCT administration eliminated the potential OS benefit. To explore this London et al.
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used causal-inference methods to estimate potential OS benefit under two hypothetical scenarios: (1) no auto-SCT was performed and (2) if patients received auto-SCT administration that was optimized for their initial response status. The analyses confirmed lack of benefit for topotecan þ cyclophosphamaide regimen. A key assumption required for this method is that the probability that a given patient received or did not receive auto-SCT depends exclusively on patient's treatment arm and whether or not the patient responds. However, this assumption cannot be validated from the study data. 3 In conclusion, validity of the causal-inference models for non-intent-to-treat analyses of RCTs depends on the unverifiable assumptions underlying these models. Interpretation of such inferences should always be done in the context of the plausibility of these assumptions.
Competing risks
The third area with relevance to establishing causal relationships between a treatment and clinical outcome is competing risks. In this situation, the outcome is the time to a certain clinical event and the patient may experience several other events, with occurrence of one event precluding occurrence of another (for example, a patient who died in remission cannot relapse). Because of the natural desire to account for the fact that some patients are 'removed' from the possibility of having the event of interest by a competing event, special cumulative-incidence-based methods for analysis of competing risk data has been proposed (see Klein et al. 39 for discussion and detailed references). (In contrast to the traditional cause-specific analysis that censors patients who experience the competing event first, the cumulative-incidence approach considers these patients incapable of having the event of interest from the time of the competing event to the end of follow-up. 40 ) In particular, Scrucca et al. 41 and Kim 42 discuss use of cumulativeincidence methods for estimating probability of relapse with treatment-related mortality as a competing risk event. However, cumulative-incidence-based evaluation of relative treatment effect should be considered with caution as the causal relationship between treatment and clinical benefit is generally confounded. This is because cumulative-incidence curves reflect the treatment effect on both the primary and the competing event(s). Thus, it is impossible to distinguish whether the decrease in the observed cumulative incidence of the primary event is caused by the treatment reducing the risk of the primary event among the patients for whom that event is a possibility or because the treatment increases the risk of the competing event(s) (and thus makes patients incapable of having the primary event). As a result, cumulative-incidence-based methods for estimating treatment effect on the event of interest may be misleading in representing causal relationship between treatment and the clinical benefit. 43 For example, if a new treatment is not effective but has a higher treatment-related mortality rate relative to the control treatment, then cumulative-incidencebased inference could suggest that the new treatment is beneficial as measured by reduction in the cumulative incidence of relapse (because a higher proportion of experimental arm patients will be 'prevented' from relapsing by treatment-related mortality). This is illustrated by results from Alyea et al. 44 that compared myeloablative and nonmyeloablative AHSCT (this was a non-randomized study but it is immaterial for the current discussion). The reported 3-year cumulative incidence of relapse was 30% after myeloabalative AHSCT vs 46% after non-myeloablative AHSCT (P ¼ 0.052). However, the corresponding 3-year cumulative incidences of treatment-related mortality were 50% after myeloablative AHSCT vs 32%, after nonmyeloablative AHSCT (P ¼ 0.01). Thus, the cumulativeincidence analysis cannot tell whether the observed improvement in relapse was caused by myeloablative AHSCT actually delaying relapses or by the fact that a higher proportion of patients receiving myeloablative AHSCT died from their treatment before having a chance of relapse. Relapse-free survival may be a more relevant end point for measuring clinical benefit in this setting.
In summary, in settings where patients may experience multiple competing types of failure, the causal effect of the treatment on a given failure type may be confounded by the treatment effect on the competing types of failure. Therefore, assessment of the causal relationship between a treatment and clinical benefit is best addressed by the overall failure rate.
Discussion
While the debate about the role of non-randomized studies and comparisons in guiding clinical practice is ongoing, 5, [45] [46] [47] [48] [49] empirical evidence seems to suggest that utmost caution is warranted: the list of examples in important public-health settings where the strong expectation of benefit from non-randomized studies has been replaced later by evidence of inefficacy or even harm is unfortunately long and telling (Table 1 ). In addition to the story of HDCT in breast cancer, it includes hormone replacement therapy for menopausal women (where instead of an expected 40-50% reduction in coronary diseases, 50 randomized data suggested that hormone replacement therapy carries increased risk of coronary disease ), randomized data showed increased increase in lung cancer incidence on the b carotene arm 53, 54 ), vitamin E for coronary heart disease (where large, well-designed RCTs showed no reduction cardiovascular event rate, 55, 56 contrary to the benefit reported in the observational studies 57, 58 ) and arthroscopic knee surgery (that was reported to reduce pain in numerous uncontrolled studies 59 and is widely used in the treatment of osteoarthritis yet has not been shown to provide any benefit in randomized trials 59, 60 ). These and other examples (Table 1) suggest that in most situations, the public health is best served by a balanced approach where preliminary evidence from non-randomized studies or analyses is confirmed by an appropriately designed RCT before a therapy is accepted for wide clinical practice.
